Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)

被引：0
|
作者：
Segal, N. H. [1 ]
Reidy-Lagunes, D. [1 ]
Capanu, M. [1 ]
Kemeny, N. [1 ]
Chung, K. [1 ]
Kelsen, D. [1 ]
Hollywood, E. [1 ]
Goodman-Davis, N. [1 ]
Saltz, L. B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [42] Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.
    Desjardins, Annick
    Vredenburgh, James J.
    Peters, Katherine B.
    Threatt, Stevie
    Herndon, James Emmett
    Sampson, John Howard
    Friedman, Allan H.
    Friedman, Henry S.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [44] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [45] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2013, 31 : 183 - 191
  • [46] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
  • [47] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [48] FOLFOX / Bevacizumab (Beva) plus /- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Schmoll, H. J.
    Garlipp, B.
    Junghanss, C.
    Leithauser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
    Rudek, Michelle A.
    Dasari, Arvind
    Laheru, Daniel
    He, Ping
    Jin, Runyan
    Walker, Rosalind
    Taylor, Gretchen E.
    Jimeno, Antonio
    Donehower, Ross C.
    Hidalgo, Manuel
    Messersmith, Wells A.
    Purcell, W. Thomas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 966 - 973
  • [50] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Trafalis, Dimitrios T.
    Alifieris, Constantinos
    Stathopoulos, George P.
    Sitaras, Nikolaos
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 713 - 722
12345